Read Summary

Adding apalutamide to androgen-deprivation therapy leads to a fast, sustained drop in PSA levels in patients with nonmetastatic castration-resistant prostate cancer, and this reduction is linked with better outcomes, according to a post hoc analysis of data from the SPARTAN trial.
Reuters Health Information

Print Friendly, PDF & Email